Analysts Set Expectations for BioVie Q3 Earnings

BioVie Inc. (NASDAQ:BIVI) – Research analysts at Brookline Capital Management issued their Q3 2025 earnings per share (EPS) estimates for BioVie in a note issued to investors on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian anticipates that the company will post earnings of ($0.32) per share for the quarter. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. Brookline Capital Management also issued estimates for BioVie’s Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($1.63) EPS.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.46) EPS for the quarter.

BioVie Stock Performance

BioVie stock opened at $1.12 on Friday. The stock has a market cap of $20.67 million, a PE ratio of -0.11 and a beta of 0.51. BioVie has a one year low of $0.99 and a one year high of $7.50. The stock has a fifty day moving average of $1.60 and a 200 day moving average of $2.12.

Institutional Trading of BioVie

A number of hedge funds have recently bought and sold shares of BIVI. NewEdge Advisors LLC increased its position in BioVie by 14,000.0% in the fourth quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock worth $28,000 after buying an additional 14,000 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in BioVie in the fourth quarter worth about $28,000. Northern Trust Corp purchased a new stake in BioVie in the fourth quarter worth about $34,000. Two Sigma Investments LP purchased a new stake in BioVie in the fourth quarter worth about $57,000. Finally, Prosperity Wealth Management Inc. purchased a new stake in BioVie in the fourth quarter worth about $63,000. Hedge funds and other institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.